Crawford 'blatantly violated' principles

Share this article:
Former FDA commissioner Lester Crawford's criminal behavior while in office was “blatant,” according to District of Columbia US Attorney Jeffrey A. Taylor in a statement issued after Crawford pled guilty to two misdemeanor charges.

"One of the most important principles of our ethics laws is that public officials cannot have a financial interest in any decision that they make," Taylor said in a Justice Department press release with HHS Inspector General Daniel Levinson.

"Lester Crawford, who held one of the most important jobs in government, blatantly violated these principles," Taylor said.
The press release said that in July 2004 he disclosed his ownership of Sysco (worth $78,000) and Kimberly-Clark ($62,000) stock that six months previously he had falsely stated he had sold. Despite that disclosure, the press release said that Crawford in two other filings six months later failed to disclose owning those same, already-disclosed stocks. Crawford did not sell the Sysco stock until 10/25/04 and the Kimberly-Clark stock until 8/18/05.

The release said Crawford's plea to making false writings was based on his failure to disclose his and his wife's ownership of stock in "significantly regulated organizations" to the Senate committee which confirmed him as commissioner and to the Executive Branch which annually took disclosure statements from him. His plea to conflict of interest was based on his ownership of the Sysco and $62,000 worth of Pepsico stock while chairing deliberations of FDA's Obesity Working Group in which both companies and their share holders had a financial interest.
Crawford's attorney was reported by the Dow Jones news service as saying he could get up to six months in jail or house arrest and a fine of up to $50,000 when he is sentenced in January.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...